Bachem Holding AG (BANB) - Total Assets
Based on the latest financial reports, Bachem Holding AG (BANB) holds total assets worth CHF2.11 Billion CHF (≈ $2.67 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Bachem Holding AG liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Bachem Holding AG - Total Assets Trend (2002–2025)
This chart illustrates how Bachem Holding AG's total assets have evolved over time, based on quarterly financial data. For live market cap, price, and company overview, see Bachem Holding AG market capitalisation.
Bachem Holding AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Bachem Holding AG's total assets of CHF2.11 Billion consist of 34.5% current assets and 65.5% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 1.5% |
| Accounts Receivable | CHF188.20 Million | 8.9% |
| Inventory | CHF494.43 Million | 23.5% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF27.94 Million | 1.3% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Bachem Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Bachem Holding AG book value and equity for net asset value and shareholders' equity analysis.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bachem Holding AG's current assets represent 34.5% of total assets in 2025, a decrease from 58.3% in 2002.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2025, down from 25.1% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 23.5% of total assets.
Bachem Holding AG Competitors by Total Assets
Key competitors of Bachem Holding AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rongsheng Petrochemical Co Ltd
SHE:002493
|
China | CN¥392.92 Billion |
|
Sichuan Chemical Co Ltd
SHE:000155
|
China | CN¥28.26 Billion |
|
Suzhou Hesheng Special Material Co Ltd
SHE:002290
|
China | CN¥2.02 Billion |
|
Shenzhen Senior Technology Material Co Ltd
SHE:300568
|
China | CN¥25.67 Billion |
|
Guangdong Rongtai Industry Co Ltd
SHG:600589
|
China | CN¥3.02 Billion |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
China | CN¥15.59 Billion |
|
Tronox Holdings PLC
NYSE:TROX
|
USA | $6.22 Billion |
|
Rastar Environmental Protection Materials Co.Ltd.
SHE:300834
|
China | CN¥3.98 Billion |
Bachem Holding AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 2.93 | 2.56 |
| Quick Ratio | 0.57 | 1.33 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF321.31 Million | CHF541.80 Million | CHF214.98 Million |
Bachem Holding AG - Advanced Valuation Insights
This section examines the relationship between Bachem Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.43 |
| Latest Market Cap to Assets Ratio | 2.25 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | CHF2.11 Billion |
| Market Capitalization | $4.74 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Bachem Holding AG's assets at a significant premium (2.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Bachem Holding AG's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bachem Holding AG (2002–2025)
The table below shows the annual total assets of Bachem Holding AG from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF2.11 Billion ≈ $2.67 Billion |
+9.66% |
| 2024-12-31 | CHF1.92 Billion ≈ $2.43 Billion |
+14.27% |
| 2023-12-31 | CHF1.68 Billion ≈ $2.13 Billion |
+21.61% |
| 2022-12-31 | CHF1.38 Billion ≈ $1.75 Billion |
+6.57% |
| 2021-12-31 | CHF1.30 Billion ≈ $1.64 Billion |
+82.66% |
| 2020-12-31 | CHF710.88 Million ≈ $898.75 Million |
+9.85% |
| 2019-12-31 | CHF647.14 Million ≈ $818.16 Million |
+5.28% |
| 2018-12-31 | CHF614.70 Million ≈ $777.15 Million |
+12.86% |
| 2017-12-31 | CHF544.65 Million ≈ $688.59 Million |
+9.70% |
| 2016-12-31 | CHF496.51 Million ≈ $627.72 Million |
+11.87% |
| 2015-12-31 | CHF443.83 Million ≈ $561.12 Million |
+2.03% |
| 2014-12-31 | CHF435.01 Million ≈ $549.97 Million |
-0.86% |
| 2013-12-31 | CHF438.78 Million ≈ $554.73 Million |
-3.63% |
| 2012-12-31 | CHF455.31 Million ≈ $575.63 Million |
-1.02% |
| 2011-12-31 | CHF460.00 Million ≈ $581.56 Million |
+0.30% |
| 2010-12-31 | CHF458.64 Million ≈ $579.85 Million |
-3.33% |
| 2009-12-31 | CHF474.43 Million ≈ $599.81 Million |
+3.74% |
| 2008-12-31 | CHF457.32 Million ≈ $578.17 Million |
+6.58% |
| 2007-12-31 | CHF429.07 Million ≈ $542.46 Million |
-2.98% |
| 2006-12-31 | CHF442.24 Million ≈ $559.10 Million |
+8.33% |
| 2005-12-31 | CHF408.21 Million ≈ $516.09 Million |
+8.85% |
| 2004-12-31 | CHF375.01 Million ≈ $474.12 Million |
+5.34% |
| 2003-12-31 | CHF355.99 Million ≈ $450.07 Million |
+3.49% |
| 2002-12-31 | CHF343.99 Million ≈ $434.90 Million |
-- |
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commerci… Read more